Riskpilot← Back to searchSign inGet full accessNeoscience Incentive AB
ABActiveOrg 5591169429HuddingeResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20170 employees
Revenue 2025
SEK 0
EBITDA margin
—
Equity ratio
59.9%
Financial strength
Net profit 2025
SEK -1K
-18% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK 0 | — |
| Net profit | SEK -1K | -18% |
| Total assets | SEK 64K | +1% |
| Equity | SEK 39K | -1% |
| Employees | 0 | — |
Legal name
Neoscience Incentive AB
Org number
5591169429
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27 juni 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-11-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall äga aktier och andelar i andra företag, handla med värdepapper, bedriva utveckling, tillverkning, handel och service av teknisk utrustning, samt framtagning av diagnostiska metoder, företrädesvis för tillämpning inom medicin, ävensom idka därmed förenlig verksamhet.
Address
Huddinge
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | −0 |
| EBITDA | — | −3 | — | −1 | 0 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −3 | 0 | −1 | 0 |
| Net financials | — | — | — | — | 0 |
| Profit before tax | 0 | −3 | 0 | −1 | 0 |
| Tax | −0 | −0 | −0 | −0 | −1 |
| Net profit | 0 | −3 | 0 | −1 | −1 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 58 | 56 | 56 | 64 | 64 |
| Equity | 43 | 40 | 40 | 39 | 39 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 16 | 16 | 16 | 26 | 26 |
| Total debt | 16 | 16 | 16 | 26 | 26 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212025
Equity ratio
59.9%
This company
38.2%
Market median
+57% vs market
20212025
Return on equity
-3.1%
This company
18.4%
Market median
-117% vs market
20212025
Net profit margin
-117900.0%
This company
8.1%
Market median
-1455656% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-12-01 – 2025-11-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-11-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neoscience Incentive AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Olof Herdensjö | Deputy Board Member | 0 companies |
| Ulf Göran Peter Fagerlin | Board of Directors | 0 companies |